

# The Goldman Guide

December 26, 2011

Volume 2, Number 31

### In This Issue

Goldman Small Cap Research Scorecard

**Picks and Pans** 

Sponsored Research Performance

Wait Till Next Year

## Goldman Small Cap Research Scorecard

Happy Holidays to everyone!

As we near year-end, we thought it would be timely to review in detail the performance of our stock picks and pans of the past year. We were very surprised at the numbers and we think you will be as well. We have the recommendations divided into 3 categories, in order to provide pure segment return figures.

We endeavor to provide as much transparency as possible, in all cases, and we are proud of our overall performance, given the difficult market conditions. We remain here to serve you, the investor, and we will be introducing a brand new website, along with new tools and services to help you along your investing journey.

## Picks and Pans

Since late November, and on an accelerated basis since just before Thanksgiving, we have gone back to our roots, and provided stock picks and pans in the small cap and midcap stock spaces, via *The Goldman Guide* and special reports. We will continue to do so as you will see beginning in January 2012.

As illustrated by the table below, the ten small cap/midcap buy recommendations rose an average of 11.6%, with 7 up and 3 down. What is most interesting is that the picks were made from late September 2011 through early December. Two of the three losers declined by 3% while the other dropped by 13%.

The big winner, Charming Shoppes, jumped 48%, while three others increased by at least 16%, year-to-date.

### Picks:

GSCR Scorecard
Small Cap/Mid Cap Picks

Stock	Date	Price	12-23-11 Price	Return
MLI	18-Sep	\$45.13 \$38.92		-13.8%
PNRA	21-Oct	\$111.70	\$140.10	25.4%
DRI	21-Oct	\$47.17	\$45.70	-3.1%
RRGB	21-Oct	\$24.38	\$28.95	18.7%
JEF	4-Nov	\$12.07	\$14.02	16.2%
EBAY	11-Nov	\$31.76	\$30.83	-2.9%
GLUU	23-Nov	\$2.78	\$3.29	18.3%
QCCO	23-Nov	\$3.80	\$3.83	0.8%
CHRS	23-Nov	\$3.32	\$4.91	47.9%
LOV	9-Dec	\$3.30	\$3.57	8.2%
Avg Return				11.6%

Clearly, this small cap/mid cap stock-picking success, leverages upon our 20+ years of work in the Wall Street analyst and mutual fund management roles. We are confident that these types of returns will be generated from our picks going forward, although there is no assurance of this type of execution.

As to the current picks above, the upside for CHRS is a bit limited, but the others, in our view, remain attractive. We will monitor and provide insights on a more formal basis, going forward.

### Pans:

When we published our Special Thanksgiving Treats and Turkeys report, we not only included 3 treats mentioned above, but 3 stocks that should be sold. While only one of the 3 is down, and down substantially, it should be noted that until recently, all 3 were down several percentage points in just 4 weeks, while the market has risen 6% or more.

# GSCR Scorecard Small Cap/Mid Cap Pans

Stock	Date	Price	12-23-11 Price	Return
COSI	23-Nov	\$0.67	\$0.68	1.5%
RF	23-Nov	\$3.90	\$4.39	12.6%
NVLT	23-Nov	\$0.75	\$0.50	-33.3%
GRPN*		\$26.11	22.84	
Avg Return				-6.4%

We should note that since NVLT completed a financing, the stock has plummeted. We are still not big believers in the science, and think it can still decline from current levels. Although NVLT shares characteristics with the sponsored group, since we place din our special report, its performance is listed here. We remain bearish on COSI and RF (Regions Financial), despite the recent financials rally.

GRPN, or Groupon, is an interesting animal. We panned it big time weeks before the IPO, and then touted as a possible trade post-IPO, but a lousy investment. However, since it was not a formal "Sell" recommendation, we are not including it in any performance results. We should note that it has declined well over 15% from the IPO price and even reached a low of \$15. Ouch.

## Sponsored Research Performance

We have segmented our small cap and mid cap performance results from our sponsored research results for 2 reasons. First, our sponsored research recommendations tend to be either micro cap or very thinly traded. Second, as they are largely event-driven rather than fundamentally-driven, the stocks are subject to price swings and greater risk.

Although we have been compensated for the research produced, we screen each company very carefully, and feel as confident about these recommendations as any other.

We readily admit we are not infallible, and we would describe the performance in this segment in one word: Awful.

# GSCR Scorecard Sponsored Micro Cap Picks

Stock	Date	Price	Peak Price	Price - Peak	12-23-11 Price	YTD Return
IBIO	4-Jan	\$3.34	\$6.06	81.4%	\$0.78	-76.6%
SSIE	8-May	\$3.10	\$5.00	61.3%	\$3.84	23.9%
NVLX	9-May	\$0.026	\$0.104	300.0%	\$0.045	73.1%
OCLS	19-Jun	\$1.60	\$1.92	20.0%	\$1.13	-29.4%
RNN	18-Sep	\$1.17	\$1.21	3.4%	\$0.44	-62.4%
MIMV	4-Nov	\$0.29	\$0.29	0.0%	\$0.13	-55.2%
ECTH	18-Nov	\$0.35	\$0.38	8.6%	\$0.34	-2.9%
OMVE	24-Nov	\$0.39	\$0.35	-10.3%	\$0.13	-66.7%
SRPX	25-Nov	\$0.75	\$0.80	6.7%	\$0.56	-25.3%

Avg Return	52.3%	-24.6%

A few important points on an overall basis are in order. First, given the wide variance in price swings and short-term trading nature of some of our subscribers, we felt it was important to note that while year-to-date the performance is poor, the returns from initiation price to the peak was very strong. Thus, for those investors with a short-term horizon and disciplined approach, strong returns were likely recorded. For the buyand-hold investors, only 2 of the 9 companies' shares are up since initiation.

It should be noted that while IBIO and RNN were NOT sponsored reports, we elected to place the stocks in this group, as they shared characteristics with these stocks rather than the other group.

We are still favorable on all of the stocks listed above. NVLX is progressing with its acquisition and on the development front, and is likely down due to not meeting previous timetables. In our view, that should not change investors' sentiment about the Company's prospects.

SSIE remains a profitable stalwart, and we expect it will list on NASDAQ soon, providing it a boost higher. Management is very strong and is building a company that will be the dominant player in its niche segment.

Although MIMV's performance is well below par, investors should ignore the current share decline and take advantage of the current, short-term, thin-trading. We are very confident it will be much closer to \$1.00 in 1H12. The company is on the cusp of executing great things, in our opinion.

Finally, our 3 most recent picks are mixed. OMVE's trading since initiation is a disaster, but the model holds true. ECTH appears very strong, and SRPX has had some great news of late which we think will generate considerable interest in the stock as the Street fully understands its significance.

This table is a reminder that perhaps taking *some* profits on price climbs is not a bad idea, given the huge average increase in stock price from initiation to its peak price, post-initiation. Nonetheless, longer term, we still believe that investors will win out.

### Wait Till Next Year

All in all, our performance surprised us and we are very pleased, especially on the small cap/mid cap side. We will keep you informed of upcoming changes to the website and our offerings to help you grow your investment portfolio to higher levels next year. These will include new research, blogs, and conference calls with our research personnel and with major Wall Street players, plus company CEOs.

In the meantime, be on the lookout for our Top Twelve Predictions for 2012 later this week.

Until then...

#### **Analyst: Robert Goldman**

Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

#### **Analyst Certification**

I, Robert Goldman, hereby certify that the view expressed in this newsletter report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

#### Disclaimer

This newsletter was prepared for informational purposes only. *Goldman Small Cap Research*, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research*, which typically highlights small cap and mid cap companies, and *Goldman Opportunity Research*, which includes micro cap companies. The *Select* product reflects the Firm's internally generated stock ideas while the *Opportunity* product reflects sponsored research reports.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company's individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

During 2011, the Firm was compensated for its research services on the following companies mentioned in this newsletter: SunSi Energies, Inc., Nuvilex, Inc., Oculus Innovative Sciences, Inc., Mimvi, Inc., EcoTECH Energy Group, Inc., Omni Ventures, Inc., Scorpex, Inc. Please read the disclaimers found on the initiation reports for compensation disclosure and research subscription terms.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A *Goldman Small Cap Research* report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This report or newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report or newsletter does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT OR NEWSLETTER IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com